JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Deshpande, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Deshpande, L. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2003, p. 4004-4005, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.4004-4005.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Distribution of fsr among Enterococcus faecalis Isolates from the SENTRY Antimicrobial Surveillance Program


   LETTER
Top
 Letter
References
 
Pillai and colleagues (3) in 2002 reported a striking correlation (100.0% positive; P = 0.005) of the fsr virulence gene with Enterococcus faecalis isolated from a collection of endocarditis cases. The comparison group of stool culture isolates had a significantly lower rate of positive fsr tests (53%) by methods described earlier by Qin et al. (4, 5). The fsr locus has been noted to be widely distributed in E. faecalis (70% of isolates) and regulates virulence-associated gelatinases and serine proteases (4, 5).

To expand the understanding of fsr related to contemporary prevalence, we screened a collection of E. faecalis isolates from the SENTRY Antimicrobial Surveillance Program selected to achieve a broad range of infection types, geographic samplings, years of isolation, and antibiogram features (vancomycin only). A total of 109 strains were chosen from the 1999 to 2002 SENTRY Program organism bank for the United States, Canada, Latin America, and Europe. Strains were single, unique infection episodes without duplication of strains (pulsed-field gel electrophoresis screened) indexed by patient or medical center. A total of 49 medical centers contributed samples of E. faecalis distributed geographically as follows: United States (59 strains; 24 centers), Canada (9 strains; 7 centers), Latin America (19 strains; 7 centers) and Europe (22 strains; 13 sites). These strains occurred among documented infections within the monitored years at the following body sites in patients residing in intensive care units (11 strains) or in general hospital wards (9 strains): bloodstream (51 strains sampled in all regions), lower respiratory tract (7 strains; United States only), skin and soft tissue (27 strains; all regions), and urinary tract (11 sites in all regions).

The fsr locus was amplified by the methods described earlier (3, 5) using the following primer sequences: 5'-AACCAGAATCGACCAATGAAT-3' (upstream primer) and 5'-GCCCCTCATAACTCAATACC-3' (downstream primer). The PCR testing conditions utilized were those published by Pillai et al. (3), and the fsr-positive E. faecalis ATCC 51299 was used as a control.

Table 1 shows the results of the PCR fsr screen for all 109 E. faecalis strains. The gene was quite ubiquitous across all infection types, geographic areas, times, and susceptibility types. The fsr-positive E. faecalis isolates were detected in 15 of 24 (62.5%) medical centers in the United States, all Canadian hospitals (100.0%), 4 of 7 (57.1%) Latin American medical centers, and 5 of 13 (38.5%) European participant hospitals (data not shown). Rates of E. faecalis isolates with fsr were highest (63.6 to 88.9%) among urinary tract infection isolates (Table 1) and lowest for the bloodstream infection strains (23.5%). These findings were consistent across all regions where samples were available. Less variation in the prevalence of the fsr was noted between geographic samples of all specimen types combined. Highest fsr-positive E. faecalis rates were encountered in North America (42.4 to 44.4%). All four vancomycin-resistant E. faecalis strains were fsr positive (three isolates from the United States [New York and Massachusetts] and one isolate from Brazil).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Occurrences of fsr-positive strains of E. faecalis in various SENTRY Antimicrobial Surveillance Program objectives (body sites of infection) and geographic areas and nations and among vancomycin-resistant strains (109 isolates)a

 
These results broaden the understanding of the fsr range among contemporary isolates of E. faecalis in the Americas and Europe. The prevalence of fsr can differ significantly among isolates when comparing types (sites) of infection and among geographic areas. The high prevalence in urinary tract infections described here was similar to the finding of other E. faecalis surface proteins (esp) associated with ascending urinary tract infections (6) and among hospitalized patients with antimicrobial-resistant clones (1). In contrast, the fsr-positive rate was low (23.5%) compared to that of the bacteremic endocarditis isolates reported by Pillai et al. (3), indicating a distinct difference between these two types of blood culture isolates. Some investigators have also reported that putative virulence factors among E. faecalis did not contribute to increased mortality rates (7). Other enterococcal virulence factors may be greater contributors to invasive disease and have measurable effects on patient outcomes (7).

These reported findings must be further documented by resistance surveillance networks using a larger selection of enterococcal virulence genes, especially with our discovery of all of the vancomycin-resistant E. faecalis isolates (four strains) being fsr positive. Finally, these enterococcal virulence factors appear to be more prevalent among human isolates of enterococci (34.5 to 41.7%) compared to those of strains of swine or poultry origin (6 of 276 samples; 2.2%), thus minimizing food animals as a significant reservoir and source of these genetic elements (A. M. Hammerum and L. B. Jensen, Letter, J. Clin.Microbiol. 40:4396, 2002). We encourage expanded studies of these genes among human and environmental enterococcal strains to determine their epidemiologic significance.


   REFERENCES
Top
 Letter
 References
 

  1. Coque, T. M., R. Willems, R. Canton, R. Del Campo, and F. Baquero. 2002. High occurrence of esp among ampicillin-resistant and vancomycin-susceptible Enterococcus faecium clones from hospitalized patients. J. Antimicrob. Chemother. 50:1035-1038.[Abstract/Free Full Text]
  2. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  3. Pillai, S. K., G. Sakoulas, H. S. Gold, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., and R. T. Inouye. 2002. Prevalence of the fsr locus in Enterococcus faecalis infections. J. Clin. Microbiol. 40:2651-2652.[Abstract/Free Full Text]
  4. Qin, X., K. V. Singh, G. M. Weinstock, and B. E. Murray. 2000. Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. Infect. Immun. 68:2579-2586.[Abstract/Free Full Text]
  5. Qin, X., K. V. Singh, G. M. Weinstock, and B. E. Murray. 2001. Characterization of fsr, a regulator controlling expression of gelatinase and serine protease in Enterococcus faecalis OG1RF. J. Bacteriol. 183:3372-3382.[Abstract/Free Full Text]
  6. Shankar, N., C. V. Lockatell, A. S. Baghdayan, C. Drachenberg, M. S. Gilmore, and D. E. Johnson. 2001. Role of Enterococcus faecalis surface protein esp in the pathogenesis of ascending urinary tract infection. Infect. Immun. 69:4366-4372.[Abstract/Free Full Text]
  7. Vergis, E. N., N. Shankar, J. W. Chow, M. K. Hayden, D. R. Snydman, M. J. Zervos, P. K. Linden, M. M. Wagener, and R. R. Muder. 2002. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin. Infect. Dis. 35:570-575.[CrossRef][Medline]
Ronald N. Jones*
Tufts University School of Medicine
Boston, Massachusetts

Lalitagauri M. Deshpande
The JONES Group/JMI Laboratories, Inc.
North Liberty, Iowa

* Phone: (319) 665-3370
Fax: (319) 665-3371
E-mail: ronald-jones{at}jmilabs.com

Journal of Clinical Microbiology, August 2003, p. 4004-4005, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.4004-4005.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Deshpande, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Deshpande, L. M.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS